You are here:

rolapitant (Varuby)

Advice

following a full submission:

rolapitant (Varuby®) is accepted for restricted use within NHS Scotland.

Indication under review: Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy.

SMC restriction: as a first-line option in adults undergoing highly emetogenic chemotherapy (HEC).

In phase III studies of patients scheduled to receive highly or moderately emetogenic chemotherapy, a greater proportion of patients treated with rolapitant-based combination therapy achieved a complete response (defined as no emesis or use of rescue medication) in the delayed phase (>24 to 120 hours after initiation of chemotherapy) of cycle one compared with combination therapy alone.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of rolapitant. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: rolapitant (Varuby)
SMC Drug ID: 1266/17
Manufacturer: Tesaro UK Ltd
Indication: Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy.
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 September 2017

Back